logo
ESET helps MSPs by integrating with the Kaseya VSA X RMM solution

ESET helps MSPs by integrating with the Kaseya VSA X RMM solution

Business Upturn22-04-2025
ESET launches a new integration of its ESET Endpoint product with the Kaseya VSA X remote monitoring and management (RMM) solution.
MSP admins will find their workloads simpler, due to less time spent managing multiple solutions, giving them more space for their daily tasks.
BRATISLAVA, Slovakia, April 22, 2025 (GLOBE NEWSWIRE) — ESET, a global leader in cybersecurity solutions, today announced the launch of another major integration, this time, with the Kaseya VSA X remote monitoring and management (RMM) software.
ESET has worked with MSPs for a long time, creating successful programs such as the ESET MSP Program, with subscription flexibility (pay only for what's in use, no flat rates, no long-term commitment), co-management (independent seat count adjustment and subscription management), or tier-based volume pricing (the more licenses sold, the better the unit price), among others.
Thus, we understand the needs of our partners as well as their clients. Among these is an interest in running efficient workloads, cutting down on time spent in 'swivel chair' operations, and simplifying their use of multiple products, while not sacrificing on their security postures.
Such results are only achievable through integrations, which ESET identifies as a key contemporary trend. As a partner- and channel-focused cybersecurity vendor, we understand this, and we develop and maintain support for all the most prevalent RMM and PSA tools out there, now joined by Kaseya VSA X, a leading RMM product.
Thanks to this new integration, users of Kaseya VSA X can now also serve organizations that use ESET. In essence, it enables MSPs to deploy and manage ESET Endpoint products directly from within the Kaseya VSA X interface, so they can perform their necessary management actions without having to log in to a separate console.
With support for additional workflows, MSPs can set up automatic actions for common scenarios. For instance, a workflow can be used to automatically deploy ESET to a freshly provisioned machine, or a workflow could be configured to provide a notification in case a threat is detected on an endpoint.
Some other key features are: 'One Click' or automated deployment of ESET Endpoint products
of ESET Endpoint products Monitoring of endpoint health (product, version, protection status)
of endpoint health (product, version, protection status) On-demand tasks such as scanning and activation
'We've been working with MSPs for a very long time, and ESET is a favorite vendor among thousands of MSPs across the world,' said Rob Jones, Global Channel Business Developer at ESET. 'With the features provided through our new integration with Kaseya VSA X software, MSP administrators will unlock extensive benefits, such as simpler workflows, easier monitoring, as well as enhanced time savings. We know what MSPs need, and with this integration, we are directly addressing multiple pain points to make their businesses more efficient.'
Version 1.0 of this integration will support Windows endpoints that are running ESET Endpoint Antivirus, Endpoint Security, or Server Security.
ESET will be continuing its integration journey, so stay tuned for more updates in the future. In the meantime, feel free to check out our ESET integrations webpage to see the list of our existing partners and connections.
About ESET
ESET® provides cutting-edge digital security to prevent attacks before they happen. By combining the power of AI and human expertise, ESET stays ahead of emerging global cyberthreats, both known and unknown— securing businesses, critical infrastructure, and individuals. Whether it's endpoint, cloud, or mobile protection, our AI-native, cloud-first solutions and services remain highly effective and easy to use. ESET technology includes robust detection and response, ultra-secure encryption, and multifactor authentication. With 24/7 real-time defense and strong local support, we keep users safe and businesses running without interruption. The ever-evolving digital landscape demands a progressive approach to security: ESET is committed to world-class research and powerful threat intelligence, backed by R&D centers and a strong global partner network. For more information, visit www.eset.com or follow our social media, podcasts and blogs.
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Fixed Price Contracts Dominate, Offering Stability in Catering Agreements
Fixed Price Contracts Dominate, Offering Stability in Catering Agreements

Yahoo

timean hour ago

  • Yahoo

Fixed Price Contracts Dominate, Offering Stability in Catering Agreements

Key market opportunities in the global contract catering sector include capitalizing on evolving consumer preferences for healthier, diverse options, leveraging the outsourcing trend for operational efficiency, emphasizing sustainability, and integrating technological advancements. Europe dominates, driven by workplace well-being and stringent regulations. Contract Catering Market Dublin, Aug. 15, 2025 (GLOBE NEWSWIRE) -- The "Contract Catering Market Report by Contract Type, and Region 2025-2033" has been added to offering. The global contract catering market is poised for substantial growth, with its size projected to rise from USD 269.0 billion in 2024 to USD 392.1 billion by 2033, at a CAGR of 4.3% from 2025 to 2033. Key factors fueling this growth include a shift towards healthier food preferences, increased outsourcing of food services for operational efficiency, emphasis on sustainability, technological advancements, and stringent regulatory environments. Contract catering, defined by its contractual agreements, offers diverse food services to various sectors including corporate offices, educational institutions, and healthcare facilities. These arrangements enable seamless integration into client operations, offering benefits such as economies of scale, varied menu options, and adherence to quality standards. Service types range from onsite cafeterias to specialized event catering. Evolving Consumer Preferences: The increasing demand for healthier and diverse food options has driven catering companies to expand their offerings. Consumers now require plant-based, organic, and allergen-free choices, alongside transparency in sourcing. This trend enhances customer experience and provides a competitive advantage to catering companies that can adapt to these demands. Outsourcing for Operational Efficiency: Outsourcing food services has emerged as a major market driver, allowing businesses to streamline operations and cut costs while ensuring high-quality food services. This is particularly preferred in sectors like healthcare and education aiming for nutritious meal delivery alongside resource optimization. Catering companies demonstrating operational expertise stand to benefit significantly from this trend. Sustainability and Responsible Sourcing: The focus on environmentally friendly practices and ethical sourcing is transforming the market. Catering providers are expected to source locally, minimize waste, and use eco-friendly packaging. This commitment to sustainability not only attracts eco-conscious clients but also enhances the company's reputation and compliance with broad sustainability goals. The market segmentation includes contract types (fixed price, cost plus), mode of contract (outsourced, self-operated), and end user segments (business and industry, education, healthcare, and others). Fixed price contracts and outsourced modes dominate the market due to their predictability, trust-building capabilities, and operational efficiencies. Business and industry sectors represent the largest market share, driven by the need for efficient food solutions in corporate environments and the growing importance of employee well-being and engagement. Regionally, Europe leads the contract catering market due to its rich culinary heritage, focus on employee satisfaction, and stringent food safety regulations. The emphasis on sustainability further drives this regional dominance. The competitive landscape is vibrant, with major players like ABM Catering Solutions, Aramark, and Sodexo leading the charge. Companies are leveraging diverse menus, innovative technology, and a commitment to sustainability to stay competitive. Key Attributes: Report Attribute Details No. of Pages 140 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $269 Billion Forecasted Market Value (USD) by 2033 $392.1 Billion Compound Annual Growth Rate 4.3% Regions Covered Global Companies Featured ABM Catering Solutions Amadeus Aramark Atalian Servest Barlett Mitchell Blue Apple Catering Camst Group Caterleisure Ltd. CH&CO Catering Compass Group PLC Dine Contract Catering Elior Group Fazer Food Services Interserve OCS Group Ltd. Sodexo For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Contract Catering Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DraftKings Secures Direct Mobile Sports Betting License to Operate in Missouri
DraftKings Secures Direct Mobile Sports Betting License to Operate in Missouri

Yahoo

timean hour ago

  • Yahoo

DraftKings Secures Direct Mobile Sports Betting License to Operate in Missouri

BOSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) -- DraftKings Inc. (Nasdaq: DKNG) announced today that the Missouri Gaming Commission has granted the company a direct mobile sports betting license. This direct mobile sports betting license will enable DraftKings to operate independently across the state of Missouri, without the need for affiliation with a land-based casino or professional sports team. DraftKings' online sportsbook would go live on the universal launch date currently expected for December 1, 2025, contingent on final regulatory approvals. 'We're pleased to secure one of two direct mobile licenses in Missouri — paving the way for us to bring DraftKings' industry-leading online sportsbook to fans across the state,' said Matt Kalish, President, DraftKings North America. 'Missouri is home to several professional teams and deeply passionate fanbases, and we look forward to enhancing their sports experience with a dynamic and responsible mobile platform.' Once live, Missouri will become the 29th U.S. state where DraftKings operates regulated sports betting. The company also offers regulated online sports betting in Washington D.C. and Ontario, Canada. DraftKings is dedicated to providing a fun gaming environment that all customers can enjoy responsibly in states where sports betting is legal. The company offers a suite of responsible gaming tools and resources. These include My Stat Sheet, which allows customers to monitor personalized gaming activity, and My Budget Builder, a tool that helps players set custom limits and reminders through a guided, easy-to-use experience. With a proven track record in regulated markets, DraftKings continues to expand access to innovative and responsible sports betting experiences across North America. As part of its commitment to the states in which the company operates, DraftKings is dedicated to supporting communities in times of need through its S.E.R.V.E.S. program. The program provides inclusive and responsible opportunities for people to build, create, imagine and innovate. Earlier this year, DraftKings made a charitable donation to the St. Louis Tornado Response Fund, part of the St. Louis Community Foundation, to aid recovery efforts following the devastating tornado that struck the Greater St. Louis area in May. More information about DraftKings is available at and fans can download the DraftKings mobile apps via iOS and Android here. About DraftKingsDraftKings Inc. is a digital sports entertainment and gaming company created to be the Ultimate Host and fuel the competitive spirit of sports fans with products that range across daily fantasy, regulated gaming and digital media. The company is headquartered in Boston and was launched in 2012 by Jason Robins, Matt Kalish and Paul Liberman. DraftKings' mission is to make life more exciting by responsibly creating the world's favorite real-money games and betting experiences. DraftKings Sportsbook is live with mobile and/or retail sports betting operations pursuant to regulations in 28 states, Washington, D.C. and in Ontario, Canada. The Company operates iGaming pursuant to regulations in five states and in Ontario, Canada under its DraftKings brand and pursuant to regulations in four states under its Golden Nugget Online Gaming brand. DraftKings also owns Jackpocket, the leading digital lottery courier app in the United States. DraftKings' daily fantasy sports product is available in 44 states, the District of Columbia and certain Canadian provinces. DraftKings is both an official sports betting and daily fantasy partner of the NFL, NHL, PGA TOUR, WNBA and UFC, as well as an official daily fantasy partner of NASCAR, an official sports betting partner of the NBA and an authorized gaming operator of MLB. In addition, DraftKings owns and operates DraftKings Network a multi-platform content ecosystem. DraftKings is committed to being a responsible steward of this new era in real-money gaming by developing and promoting educational information and tools to help all players enjoy our games responsibly. Forward-Looking StatementsCertain statements made in this press release are 'forward looking statements' within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. When used in this press release, the words 'estimates,' 'projected,' 'expects,' 'anticipates,' 'forecasts,' 'plans,' 'intends,' 'believes,' 'seeks,' 'may,' 'will,' 'would,' 'should,' 'future,' 'propose' and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside DraftKings' control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see DraftKings' filings with the Securities and Exchange Commission. DraftKings does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Oligonucleotide CDMO Market to Soar USD 18.37 Billion at 21.83% Strong CAGR by 2034
Oligonucleotide CDMO Market to Soar USD 18.37 Billion at 21.83% Strong CAGR by 2034

Yahoo

time2 hours ago

  • Yahoo

Oligonucleotide CDMO Market to Soar USD 18.37 Billion at 21.83% Strong CAGR by 2034

The global oligonucleotide CDMO market is valued at USD 3.11 billion in 2025 and is projected to reach approximately USD 18.37 billion by 2034, expanding at a CAGR of 21.83% over the forecast period. Ottawa, Aug. 08, 2025 (GLOBE NEWSWIRE) -- According to a study by Towards Healthcare, a sister company of Precedence Research, the global oligonucleotide CDMO market size to grow from USD 2.55 billion in 2024 and is expected to expand USD 18.37 billion by 2034. The growth of the market is driven by the increased demand for specialized techniques, which are technologically advanced due to the growing prevalence of chronic diseases in the region. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways North America dominated the oligonucleotide CDMO market in 2024. Asia Pacific is estimated to grow at the fastest CAGR during the forecast period. By service, the contract manufacturing segment led the market in 2024. By service, the contract development segment is estimated to achieve significant growth during the forecast period. By type, the ASO segment held a significant share of the market in 2024. By type, the siRNA segment is expected to grow significantly during the forecast period. By application, the therapeutic segment held the largest share of the oligonucleotide CDMO market in 2024. By application, the research segment is anticipated to grow at a significant rate during the forecast period. By end-use, the pharma segment held a major share of the market in 2024. By end-use, the biotech segment is anticipated to achieve a significant share of the market during the forecast period. Market Overview & Potential An oligonucleotide CDMO (Contract Development and Manufacturing Organization) specializes in offering comprehensive services for developing and manufacturing short oligonucleotides, which are synthetic nucleic acid sequences used in various biotech and pharmaceutical applications. These organizations provide expertise in custom synthesis, process development, scale-up, and GMP manufacturing of oligonucleotides. You can place an order or ask any questions, please feel free to contact us at sales@ What Is the Growth Potential Responsible for The Growth of The Oligonucleotide CDMO Market? The growth of the market is driven by the growing demand for personalized medicines and RNA therapeutics, which demand specialized manufacturing capabilities, which fuels the growth of the market. The increasing prevalence of chronic diseases, especially cancer and cardiovascular diseases, with advancements in oligonucleotide manufacturing to improve synthesis technologies with automated techniques, drives the growth of the market. Other key growth drivers are government support and funding, increased investment in biotechnology, globalization, and increased collaboration boost the growth of the market. What Are the Emerging Trends in the Oligonucleotide CDMO Market? Growing Demand for Oligo-based Therapies: Oligonucleotides, including antisense oligonucleotides and small interfering RNAs, are increasingly recognized as therapeutic agents because of their targeted action and specificity. Focus on Precision Medicine: The shift toward personalized treatments designed for individual patients is boosting the need for specialized oligonucleotide therapies. Increased FDA Approvals: The rising number of FDA approvals for oligonucleotide-based drugs, such as Qalsody for ALS, further fuels market growth and stimulates innovation. Cost Efficiency and Expertise: Outsourcing to CDMOs enables companies to utilize specialized knowledge and potentially lower costs associated with in-house manufacturing, particularly for complex processes. What Are the Major Challenges Facing the Oligonucleotide CDMO Market? The market encounters several notable challenges, mainly due to manufacturing complexity, regulatory obstacles, and the need for advanced expertise and infrastructure. Scaling from research to commercial volumes, achieving high purity, and ensuring delivery efficiency to target sites are significant hurdles. Evolving regulatory requirements and the need for specialized skills in oligonucleotide synthesis, purification, and conjugation also contribute to the difficulty. Get the latest insights on life science industry segmentation with our Annual Membership: Regional Insights Why Did North America Lead the Oligonucleotide CDMO Market in 2024? North America held a dominant position in 2024 due to its well-established research facilities, substantial R&D investments in peptide and oligonucleotide therapies, and a higher prevalence of chronic diseases. The demand for biopharmaceuticals like oligonucleotides and peptides supports this growth. North American CDMOs are well-equipped to meet this demand by providing specialized development and manufacturing services for these complex compounds. The market expansion is driven by ongoing investments from pharmaceutical and biotech firms into R&D, often through partnerships with CDMOs to access advanced infrastructure and expertise. High R&D investment, advanced biotech infrastructure, rising chronic disease prevalence, and strong pharmaceutical industry demand drive U.S. oligonucleotide CDMO growth. Regulatory clarity from the FDA, increasing personalized medicine focus, and government support for genomics research further enhance market expansion, fostering innovation and strategic collaborations with contract manufacturers. Government incentives for biotechnology, a skilled scientific workforce, and growing demand for precision medicine propel Canada's oligonucleotide CDMO sector. Strong academic-industry partnerships, supportive regulatory frameworks, and increasing investments from global pharma companies in Canadian CDMO facilities promote innovation, clinical trials, and manufacturing scalability within the country. Why Is Asia Pacific Projected to Show Rapid Growth in the Oligonucleotide CDMO Market? Asia Pacific is anticipated to be the fastest-growing region for oligonucleotide CDMOs during the forecast period. Countries like China, Japan, India, and South Korea are leading due to their large populations, focus on biopharmaceutical innovation, and strong healthcare investments. The region's market share has notably increased over recent years, supported by economic growth and rising prosperity, making it attractive for pharmaceutical outsourcing. This growth is further fueled by increased R&D funding and improvements in healthcare infrastructure. Rapid biotechnology expansion, government funding, and a large patient population fuel oligonucleotide CDMO growth in China. Domestic pharma companies increasingly outsource production, while favorable policies, infrastructure development, and cost advantages attract global partnerships. China's focus on RNA therapeutics and local innovation also accelerates CDMO sector maturation and competitiveness. Low manufacturing costs, a strong generic pharmaceutical base, and a growing talent pool drive India's oligonucleotide CDMO growth. Government initiatives supporting biotech innovation, rising contract research demand, and increased interest from Western firms in Indian CDMOs contribute. The expanding clinical trial ecosystem further enhances market attractiveness and outsourcing potential. Become a valued research partner with us - Segmental Insights Which Service Segment Dominated the Oligonucleotide CDMO Market in 2024? The contract manufacturing segment led the market in 2024, driven by the rising need for wide-scale, cGMP-compliant oligonucleotide APIs for clinical and commercial use. To meet the growing demand for ASOs, siRNAs, and mRNA-based therapies, CDMOs equipped with advanced solid-phase synthesis, automated fill-finish systems, and high-throughput purification are vital. This leadership is reinforced by pharmaceutical companies' reliance on CDMOs for high-purity, scalable, and globally compatible manufacturing solutions, driven by strict regulations and expansion challenges. This led to a growing and expanding influence on market growth. The contract development segment is estimated to achieve significant growth during the forecast period. Encompassing services like preclinical development, formulation, process development, and analytical techniques. These services are crucial for optimizing production processes and ensuring the safety and quality of oligonucleotides and peptides. R&D in oligonucleotide therapies is a key investment focus for pharma and biotech companies. Partnering with CDMOs allows these companies to reduce costs and accelerate product development, focusing on their core competencies. How did ASO Segment Dominated the Oligonucleotide CDMO Market in 2024? The ASO segment held a significant share of the market in 2024. Over the decades, the biotech and pharma industries have developed innovative approaches to target disease-related proteins, demanding innovation and development of new technologies and forms of products, which increases the demand for the market. RNA therapeutics, especially antisense oligonucleotides, have made significant progress in the market. Several ASO-based drugs are already FDA-approved, with many more under clinical testing. These factors support the growth and expansion of the market. The siRNA segment is expected to grow significantly during the forecast period. SiRNA technologies offer speed and specificity, helping to overcome preclinical drug development hurdles, which fuels the demand for the market. They currently assist in identifying the most promising pharmacological targets for specific diseases and are being explored for new, potent applications in drug candidate prioritization. These applications and benefits offered by the segment promote the growth and expansion of the market. Which Application Segment Dominated the Oligonucleotide CDMO Market in 2024? The therapeutic segment held the largest share of the market in 2024. Approaches have been developed to enhance the pharmacokinetics and pharmacodynamics of oligonucleotides. Historically targeted at rare diseases and niche markets, oligonucleotides now benefit large patient groups. The field is rapidly expanding despite fluctuations, with 44 companies having compounds in late-stage clinical trials or on the market. Major players include Johnson & Johnson, Roche, Novartis, and AstraZeneca, alongside specialized biotech firms like Ionis Pharmaceuticals and Alnylam Pharmaceuticals. Concurrently, there has been notable activity in oligonucleotide patents and applications influencing the growth. The research segment is anticipated to grow at a significant rate in the oligonucleotide CDMO market during the forecast period, with contributions from research institutions impacting early-stage research, innovative technologies, and scientific breakthroughs. These institutions are vital in identifying therapeutic potentials, fostering partnerships with CDMOs and pharma companies, and influencing market dynamics. Advances in distribution, analytics, and synthesis are driving market expansion, and published research influences development and manufacturing strategies. How did the pharma Segment dominate the Oligonucleotide CDMO Market In 2024? The pharma segment accounted for a major market share in 2024. The advent of oligonucleotide therapies has revolutionized medicine, with several approved in the US and EU. These include a mix of single and double-stranded polydeoxyribonucleotides, six siRNAs, twelve ASOs, and one aptamer. The growing pharma sector and the application of oligonucleotides increase the demand for manufacturing and production, which contributes to the growth and expansion of the market. The biotech segment is also expected to claim a significant market share, enabled by protein-DNA functionalization through covalent bonding. This technology facilitates the creation of therapeutic molecules with potential applications for diseases like AIDS and cancer. The ongoing research and development in the biotech sector further propels the growth and expansion of the market. Recent Developments in the Oligonucleotide CDMO Market In April 2025, Sumitomo Chemical announced the launch of its new company, Sumitomo Chemical Advanced Medical Solutions America LLC, in Massachusetts to serve as its Oligonucleotide CDMO2 business. The company will provide gRNA samples to customers by August 2025. In July 2024, Agilent Technologies announced a strategic agreement to acquire BioVectra, a specialized CDMO, for $925 million. The acquisition was made to build Agilent Technologies' CDMO specialization in oligonucleotides and CRISPR therapeutics, expanding its portfolio of services and bringing world-class capabilities to support gene editing. Browse More Insights of Towards Healthcare: The global life science CDMO market is witnessing rapid expansion, with revenues projected to reach several hundred million dollars by the end of the forecast period (2025–2034). The veterinary CRO and CDMO market was valued at USD 7.17 billion in 2024, is expected to reach USD 7.77 billion in 2025, and is projected to climb to approximately USD 16.13 billion by 2034, growing at a CAGR of 8.43% during 2025–2034. The advanced therapy medicinal products (ATMP) CDMO market stood at USD 6.73 billion in 2024, increased to USD 7.99 billion in 2025, and is forecast to surge to USD 37.27 billion by 2034, registering a CAGR of 18.82% from 2025 to 2034. The investigational new drug CDMO market was valued at USD 5.29 billion in 2024, rose to USD 5.66 billion in 2025, and is anticipated to reach USD 10.34 billion by 2034, expanding at a CAGR of 6.97% between 2025 and 2034. The mRNA therapeutics CDMO market was worth USD 4.62 billion in 2024, increased to USD 5.15 billion in 2025, and is projected to grow to USD 13.63 billion by 2034, recording a CAGR of 11.37% during 2025–2034. The CDMO services for pharma and biotech market is experiencing substantial growth from 2024 to 2034, fueled by the increasing outsourcing trend among pharmaceutical and biotechnology companies. The CDMO aseptic filling solutions market is set for strong growth throughout the forecast period, driven by rising demand for sterile manufacturing capabilities and specialized injectable therapies. The active pharmaceutical ingredients (API) CDMO market was valued at USD 127.45 billion in 2024, increased to USD 136.92 billion in 2025, and is estimated to reach USD 260.98 billion by 2034, growing at a CAGR of 7.43% from 2025 to 2034. The small molecule CDMO market stood at USD 72.81 billion in 2024, rose to USD 78.01 billion in 2025, and is forecast to hit USD 145.12 billion by 2034, expanding at a CAGR of 7.14% during 2025–2034. The topical drugs CDMO market was worth USD 46.32 billion in 2024, increased to USD 51.62 billion in 2025, and is expected to reach USD 136.71 billion by 2034, registering a CAGR of 11.43% between 2025 and 2034. Top Companies and Their Contributions to the Market Contributions & Offerings to the Oligonucleotide CDMO Market Bachem A global leader in peptide and oligonucleotide synthesis, Bachem offers full CDMO services including development, GMP manufacturing, and analytics. Thermo Fisher Scientific Inc. Provides end-to-end oligonucleotide services, from preclinical to commercial scale, leveraging advanced technologies and global infrastructure. Agilent Technologies, Inc. Offers custom oligo synthesis and quality control platforms, supporting therapeutic development with scalable manufacturing capabilities. EUROAPI Delivers active pharmaceutical ingredient (API) production, including oligonucleotides, with a focus on quality, sustainability, and innovation. ST Pharm Specializes in large-scale GMP oligonucleotide manufacturing, supplying APIs globally with expertise in modified nucleic acids and cGMP compliance. Kaneka Eurogentec S.A. Provides custom manufacturing of therapeutic oligonucleotides, with cGMP-grade synthesis, formulation, and analytical support. Ajinomoto Co., Inc. Leverages proprietary biotechnologies for oligonucleotide production, offering scale-up and process development through its CDMO division. Aurigene Pharmaceutical Offers integrated CDMO services including oligonucleotide synthesis, analytical development, and GMP manufacturing for global biopharma clients. Syngene International Provides end-to-end oligo development and manufacturing, supporting early-stage to commercial scale with regulatory expertise. PolyPeptide Group Recently expanded into oligonucleotide CDMO services, combining peptide and oligo synthesis capabilities with advanced regulatory compliance. Key Players in Oligonucleotide CDMO Market Bachem Thermo Fisher Scientific Inc. Agilent Technologies, Inc. EUROAPI ST Pharm Kaneka Eurogentec S.A. Ajinomoto Co., Inc. Aurigene Pharmaceutical Services Ltd. Syngene International Limited PolyPeptide Group WuXi AppTec Eurofins Scientific GenScript Lonza Danaher Corporation Segments Covered in The Report By Service Contract Manufacturing Clinical Commercial Contract Development By Type ASO siRNA CPG Oligos gRNA By Application Therapeutic Research Diagnostics By End-User Pharma Biotech By Region North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait Immediate Delivery Available | Buy This Premium Research @ Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. You can place an order or ask any questions, please feel free to contact us at sales@ Europe Region - +44 778 256 0738 North America Region - +1 8044 4193 44 Web: Find us on social platforms: LinkedIn | Twitter | InstagramError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store